These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26035560)

  • 21. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL;
    Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.
    Rezende PC; Hueb W; Garzillo CL; Lima EG; Hueb AC; Ramires JA; Kalil Filho R
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1105-12. PubMed ID: 22944095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction.
    Shen L; Shah BR; Nam A; Holmes D; Alexander KP; Bhatt DL; Ho PM; Peterson ED; He B; Roe MT
    Am Heart J; 2014 Jun; 167(6):840-5. PubMed ID: 24890533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing illness perceptions and adherence to dual antiplatelet therapy in patients with stable coronary disease.
    Fennessy MM; Devon HA; Ryan C; Lopez JJ; Zerwic JJ
    J Cardiovasc Nurs; 2013; 28(6):573-83. PubMed ID: 22785086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Li Y; Han Y; Zhang L; Jing Q; Wang X; Yan G; Ma Y; Wang G; Wang S; Chen X; Yang L; Zhu G; Liu H; Jiang T
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1127-33. PubMed ID: 22945767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
    Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
    Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery.
    Bauer SM; Cayne NS; Veith FJ
    J Vasc Surg; 2010 Jan; 51(1):242-51. PubMed ID: 19954922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Vavuranakis M; Maniatis K; Kokkou E; Papageorgiou N; Papaioannou S; Tourikis P; Papavassiliou AG; Stefanadis C; Tousoulis D
    Int J Cardiol; 2014 Nov; 177(1):192-6. PubMed ID: 25499376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
    Charlot M; Nielsen LH; Lindhardsen J; Ahlehoff O; Olsen AM; Hansen ML; Hansen PR; Madsen JK; Køber L; Gislason GH; Torp-Pedersen C
    Eur Heart J; 2012 Oct; 33(20):2527-34. PubMed ID: 22798561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical therapy in patients undergoing percutaneous coronary intervention: results from the ROSETTA registry.
    Eisenberg MJ; Okrainec K; Lefkovits J; Goudreau E; Deligonul U; Mak KH; Duerr R; Tsang J; Huynh T; Sedlis S; Brown DL; Brieger D; Pilote L;
    Can J Cardiol; 2003 Aug; 19(9):1009-15. PubMed ID: 12915928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
    Stone GW; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri E; Gurbel PA; Xu K; Parise H; Kirtane AJ; Brodie BR; Mehran R; Stuckey TD;
    Lancet; 2013 Aug; 382(9892):614-23. PubMed ID: 23890998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
    Park DW; Ahn JM; Song HG; Lee JY; Kim WJ; Kang SJ; Yun SC; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Am Heart J; 2013 Jan; 165(1):34-42.e1. PubMed ID: 23237131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous coronary intervention versus medical therapy in stable coronary artery disease: the unresolved conundrum.
    Epstein SE; Waksman R; Pichard AD; Kent KM; Panza JA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):993-8. PubMed ID: 24156960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.
    Cole JA; Brennan AL; Ajani AE; Yan BP; Duffy SJ; Loane P; Reid CM; Yudi MB; New G; Black A; Shaw J; Clark DJ; Andrianopoulos N
    Cardiovasc Ther; 2014 Apr; 32(2):47-51. PubMed ID: 24393169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.
    Parodi G; Bellandi B; Venditti F; Carrabba N; Valenti R; Migliorini A; Grassellini S; Ramazzotti E; Antoniucci D
    Am J Cardiol; 2012 Jan; 109(2):214-8. PubMed ID: 21996146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.